The Food and Drug Administration (FDA) is continuously approving new drugs, and we want to ensure our Clients are aware of these new approvals and drugs as they enter the market. The table below includes the drugs that are most likely to impact your plan. The full list of recent approvals can be found below the chart.
Posted: Feb 20 2017
FDA Drug Approvals
Each month the FDA approves new medications, and below is a highlight of the most relevant new approvals and/or drugs which have the potential to impact your prescription plan. While the medications below have been evaluated and approved by the FDA, they may not enter the marketplace for several weeks or months. Therefore, pricing information for these medications is typically unavailable at the time of approval.
|New Brand Approvals|
|Drug Name||Uses/Treatment||Pricing Information||Other Information|
|Trulance (plecanatide)||Treatment of chronic idiopathic constipation in adult patients||Pricing information not yet available||
|Xyzal Allergy 24 HR (levocetirizine)||Treatment of seasonal allergic ehinitis and perennial allergic rhinitis in pediatric and adult patients||Pricing information not yet available||
|Vantrela ER (hydrocodone bitartrate)||Treatment of severe pain in adult patients who require daily, around-the-clock, long-term opioid treatment||Pricing information not yet available||
Download Report as PDF